FDA Delays Off-Label Rule Opposed By Big Pharma
Bowing to pressure from Big Pharma, the U.S. Food and Drug Administration on Friday delayed by one year a controversial new rule that endorsed a broad approach to determining whether drug...To view the full article, register now.
Already a subscriber? Click here to view full article